Edwards Studies Gene Therapy Compound As Vessel For Peripheral Growth
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences' legacy as a Baxter spin-off is allowing the cardiovascular firm to pursue clinical applications of a peripheral artery disease (PAD) gene therapy compound without integrating it with a device